By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Shares of Alpha Tau Medical rose Wednesday after it said it will collaborate with Tolmar International to bring localized alpha radiation cancer therapy to prostate cancer patients in the United ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...